JP2021530456A5 - - Google Patents

Info

Publication number
JP2021530456A5
JP2021530456A5 JP2020572517A JP2020572517A JP2021530456A5 JP 2021530456 A5 JP2021530456 A5 JP 2021530456A5 JP 2020572517 A JP2020572517 A JP 2020572517A JP 2020572517 A JP2020572517 A JP 2020572517A JP 2021530456 A5 JP2021530456 A5 JP 2021530456A5
Authority
JP
Japan
Prior art keywords
crystalline salt
pharmaceutical composition
salt according
subject
diffraction pattern
Prior art date
Application number
JP2020572517A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020010068A5 (https=
JP2021530456A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/040276 external-priority patent/WO2020010068A1/en
Publication of JP2021530456A publication Critical patent/JP2021530456A/ja
Publication of JP2021530456A5 publication Critical patent/JP2021530456A5/ja
Publication of JPWO2020010068A5 publication Critical patent/JPWO2020010068A5/ja
Priority to JP2024076310A priority Critical patent/JP2024105460A/ja
Pending legal-status Critical Current

Links

JP2020572517A 2018-07-02 2019-07-02 ２−（３，５−ジクロロ−４−（（５−イソプロピル−６−オキソ−１，６−ジヒドロピリダジン−３−イル）オキシ）フェニル）−３，５−ジオキソ−２，３，４，５−テトラヒドロ−１，２，４−トリアジン−６−カルボニトリルの固体形態 Pending JP2021530456A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024076310A JP2024105460A (ja) 2018-07-02 2024-05-09 ２－（３，５－ジクロロ－４－（（５－イソプロピル－６－オキソ－１，６－ジヒドロピリダジン－３－イル）オキシ）フェニル）－３，５－ジオキソ－２，３，４，５－テトラヒドロ－１，２，４－トリアジン－６－カルボニトリルの固体形態

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862692914P 2018-07-02 2018-07-02
US62/692,914 2018-07-02
PCT/US2019/040276 WO2020010068A1 (en) 2018-07-02 2019-07-02 Solid forms of 2-(3,5-dichloro-4-((5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024076310A Division JP2024105460A (ja) 2018-07-02 2024-05-09 ２－（３，５－ジクロロ－４－（（５－イソプロピル－６－オキソ－１，６－ジヒドロピリダジン－３－イル）オキシ）フェニル）－３，５－ジオキソ－２，３，４，５－テトラヒドロ－１，２，４－トリアジン－６－カルボニトリルの固体形態

Publications (3)

Publication Number Publication Date
JP2021530456A JP2021530456A (ja) 2021-11-11
JP2021530456A5 true JP2021530456A5 (https=) 2022-07-08
JPWO2020010068A5 JPWO2020010068A5 (https=) 2022-07-08

Family

ID=67441642

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020572517A Pending JP2021530456A (ja) 2018-07-02 2019-07-02 ２−（３，５−ジクロロ−４−（（５−イソプロピル−６−オキソ−１，６−ジヒドロピリダジン−３−イル）オキシ）フェニル）−３，５−ジオキソ−２，３，４，５−テトラヒドロ−１，２，４−トリアジン−６−カルボニトリルの固体形態
JP2024076310A Pending JP2024105460A (ja) 2018-07-02 2024-05-09 ２－（３，５－ジクロロ－４－（（５－イソプロピル－６－オキソ－１，６－ジヒドロピリダジン－３－イル）オキシ）フェニル）－３，５－ジオキソ－２，３，４，５－テトラヒドロ－１，２，４－トリアジン－６－カルボニトリルの固体形態

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024076310A Pending JP2024105460A (ja) 2018-07-02 2024-05-09 ２－（３，５－ジクロロ－４－（（５－イソプロピル－６－オキソ－１，６－ジヒドロピリダジン－３－イル）オキシ）フェニル）－３，５－ジオキソ－２，３，４，５－テトラヒドロ－１，２，４－トリアジン－６－カルボニトリルの固体形態

Country Status (12)

Country Link
US (3) US20210122740A1 (https=)
EP (2) EP3818057A1 (https=)
JP (2) JP2021530456A (https=)
KR (2) KR102890565B1 (https=)
CN (1) CN112638904A (https=)
AR (1) AR115666A1 (https=)
AU (2) AU2019298236A1 (https=)
CA (1) CA3104860A1 (https=)
IL (2) IL321116A (https=)
MX (3) MX2021000107A (https=)
TW (1) TW202019914A (https=)
WO (1) WO2020010068A1 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT4406594T (lt) 2012-09-17 2025-12-29 Madrigal Pharmaceuticals, Inc. Skydliaukės hormono analogai
IL266054B2 (en) 2016-10-18 2023-10-01 Madrigal Pharmaceuticals Inc Methods for treating liver disorders or lipid disorders using a THR-BETA agonist
US12338206B2 (en) 2019-02-21 2025-06-24 Nanjing Ruijie Pharma Co., Ltd. Compounds and their uses as thyroid hormone receptor agonists
GEP20247637B (en) 2019-05-08 2024-06-25 Aligos Therapeutics Inc Modulators of thr-b and methods of use thereof
WO2021063367A1 (zh) * 2019-09-30 2021-04-08 苏州科睿思制药有限公司 一种Resmetirom晶型及其制备方法和用途
WO2021129465A1 (zh) * 2019-12-26 2021-07-01 苏州科睿思制药有限公司 一种Resmetirom晶型及其制备方法和用途
US12595254B2 (en) 2020-09-10 2026-04-07 Crystal Pharmaceutical (Suzhou) Co., Ltd. Crystal form of Resmetirom, preparation method therefor, and use thereof
WO2022086894A1 (en) 2020-10-19 2022-04-28 Teva Pharmaceuticals International Gmbh Solid state forms of resmetirom
KR20230142523A (ko) * 2021-02-01 2023-10-11 마드리갈 파마슈티칼스, 인크. 간 장애 또는 지질 장애의 치료를 위한 로수바스타틴 및 레스메티롬의 치료용 조합
CN114907327A (zh) * 2021-02-10 2022-08-16 杭州领业医药科技有限公司 Resmetirom的晶型及其制备方法和用途
WO2022225827A1 (en) * 2021-04-21 2022-10-27 Merck Sharp & Dohme Llc Novel forms of cyclic dinucleotide compounds
JP2024544538A (ja) * 2021-11-11 2024-12-03 ターンズ・ファーマシューティカルズ・インコーポレイテッド ＴＨＲ－βアゴニストによる肝障害の治療
WO2024263714A1 (en) 2023-06-22 2024-12-26 Madrigal Pharmaceuticals, Inc. BIOMARKERS FOR TREATING LIVER DISORDERS WITH THR-β AGONISTS AND RELATED USES
WO2025011259A1 (zh) * 2023-07-07 2025-01-16 苏州科睿思制药有限公司 瑞司美替罗的晶型及其制备方法和用途
CN119613386A (zh) * 2023-09-14 2025-03-14 杭州科巢生物科技有限公司 一种瑞司美替罗1,4-二氧六环溶剂化合物及其制备方法
WO2025083699A2 (en) 2023-10-16 2025-04-24 Cipla Limited Resmetirom polymorphs and process thereof
US12377104B1 (en) 2024-02-06 2025-08-05 Madrigal Pharmaceuticals, Inc. Methods for treating a fatty liver disease
WO2025171032A1 (en) 2024-02-06 2025-08-14 Madrigal Pharmaceuticals, Inc. Methods for treating a fatty liver disease
WO2025172958A1 (en) * 2024-02-16 2025-08-21 Metrochem Api Pvt Ltd Solid state forms of resmetirom
WO2025231587A1 (zh) * 2024-05-06 2025-11-13 杭州科巢生物科技有限公司 一种瑞司美替罗无水晶型ch及其制备方法
WO2026067708A1 (zh) * 2024-09-30 2026-04-02 齐鲁制药有限公司 瑞司美替罗晶型及其制备方法和用途
WO2026074443A1 (en) 2024-10-01 2026-04-09 Assia Chemical Industries Ltd. Solid state forms of resmetirom

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001051919A2 (en) * 2000-01-07 2001-07-19 Transform Pharmaceuticals, Inc. High-throughput formation, identification, and analysis of diverse solid-forms
PL1919878T3 (pl) * 2005-07-21 2011-03-31 Hoffmann La Roche Pochodne pirydazynonu jako agoniści receptora hormonu tarczycy
LT4406594T (lt) * 2012-09-17 2025-12-29 Madrigal Pharmaceuticals, Inc. Skydliaukės hormono analogai
IL266054B2 (en) * 2016-10-18 2023-10-01 Madrigal Pharmaceuticals Inc Methods for treating liver disorders or lipid disorders using a THR-BETA agonist

Similar Documents

Publication Publication Date Title
JP2021530456A5 (https=)
JPWO2020010068A5 (https=)
JP2021183628A (ja) カルビドパおよびｌ−ドーパプロドラッグならびにそれらの使用方法
JP2024105460A (ja) ２－（３，５－ジクロロ－４－（（５－イソプロピル－６－オキソ－１，６－ジヒドロピリダジン－３－イル）オキシ）フェニル）－３，５－ジオキソ－２，３，４，５－テトラヒドロ－１，２，４－トリアジン－６－カルボニトリルの固体形態
JP5036765B2 (ja) 水溶性ストロンチウム塩を用いる軟骨／骨症状の治療
JP2024105460A5 (https=)
KR100273888B1 (ko) 2,2-디클로로알칸카르복실산,그의제조방법,그를함유하는약물,및그의내인슐린치료용용도
JP2020512316A5 (https=)
EP3597628A1 (en) Salts or co-crystals of 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol
TWI303634B (en) 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,4']bipyridinyl in pure crystalline form, process for synthesis, and pharmaceutical composition containing the same
CA2614529A1 (en) Pyridazinone derivatives as thyroid hormone receptor agonists
CA2716860A1 (en) Compounds and method for reducing uric acid
CN103228618B (zh) 新化合物及其医药用途
JP2023109937A5 (https=)
JP2019516749A5 (https=)
JPWO2020257573A5 (https=)
JP2018197268A (ja) マルトール第二鉄の結晶形態
US8916609B2 (en) Compounds as L-cystine crystallization inhibitors and uses thereof
RU2009104346A (ru) Ксинафоатная соль замещенного 5-оксазол-2-ил-хинолинового соединения
JP5069690B2 (ja) 酸と第四級アンモニウムとの塩を調製するための新規な方法
RU2021132455A (ru) Новые твердые формы (2s,3s,4s,5r,6s)-3,4,5-тригидрокси-6-(((4ar,10ar)-7-гидрокси-1-пропил-1,2,3,4,4a,5,10,10a-октагидробензо[g]хинолин-6-ил)окси)тетрагидро-2h-пиран-2-карбоновой кислоты
US8859824B2 (en) Dual cation dual anion coordination complexes
JPWO2021091819A5 (https=)
RU2026106261A (ru) Полиморфы и содержащие их композиции
JPWO2023164024A5 (https=)